Marc Hafner

20PUBLICATIONS
112CO-AUTHORS
Molecular targetsGene expression (incl. microarray and other genome-wide approaches)Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Proteomics and intermolecular interactions (excl. medical proteomics)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Oct 27, 2025
PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.

Dejan Juric, Kyung Song, Radia M Johnson

|Aug 02, 2025
Epiregulon: Single-cell transcription factor activity inference to predict drug response and drivers of cell states.

Tomasz Włodarczyk, Aaron Lun, Diana Wu

|Jul 08, 2025
KRAS Codon-Specific Mutations Differentially Toggle PI3K Pathway Signaling and Alter Sensitivity to Inavolisib (GDC-0077).

Kyung W Song, Christy C Ong, Eva Lin

|Jan 10, 2025
Transformer-based modeling of Clonal Selection and Expression Dynamics reveals resistance mechanisms in breast cancer.

Nathan D Maulding, Jun Zou, Wei Zhou

|Nov 05, 2024
Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer.

M T Herrera-Abreu, J Guan, U Khalid

|Feb 22, 2024
CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape.

Nayan Chaudhary, Alejandro M Chibly, Ann Collier

Pageof 4

Frequent Collaborators

5 joint publications

Mario Niepel

4 joint publications

Ciara Metcalfe

3 joint publications

Nicole M Sodir

3 joint publications

Anwesha Dey